Journal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Volume 13, Issue 10, Pages 567-579Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrgastro.2016.128
Keywords
-
Categories
Funding
- AbbVie
- Ferring
- Janssen-Cilag
- Shire
- Lilly
- Norman Collison Foundation
- UCB
- Vifor
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Cosmo
- Giuliani SpA
- GlaxoSmithKline
- MSD
- Neovacs
- Novartis
- Novo Nordisk
- Pfizer
- Proximagen
- Receptos
- Sigmoid Pharma
- Takeda
- TopiVert
- VHsquared
- Warner Chilcott
Ask authors/readers for more resources
Therapeutic advances in the management of IBD have led to a paradigm shift in the assessment of IBD disease activity. Beyond clinical remission, objective assessment of inflammation is now critical to guiding subsequent therapy as part of a 'treat to target' strategy. Multiple domains of disease activity assessment in IBD exist, each of which has its merits, although none are perfect. The aim of this Review is to comprehensively evaluate measures of disease activity in both ulcerative colitis and Crohn's disease, including clinical, endoscopic, histological and radiological assessment tools, as well as the use of biomarkers and quality of life evaluation. A subjective appraisal of the best indices for use in clinical practice is provided, based on index validation, responsiveness and experience in clinical trials, international specialist opinion, and practicality and suitability for use in clinical practice. This Review aims to enable the reader to gain confidence in IBD disease activity assessment and to give ready access to the necessary tools.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available